Applied dna regains compliance with all nasdaq continued listing requirements

Stony brook, ny / access newswire / july 7, 2025 / applied dna sciences, inc. (nasdaq:apdn) (the "company"), a leader in pcr-based dna technologies, today announced that on july 2, 2025, it received written notice (the "compliance notice") from the nasdaq stock market llc ("nasdaq") informing the company that it has regained compliance with nasdaq listing rule 5550(a)(2), which requires that companies listed on the nasdaq capital market maintain a minimum bid price of $1.00 per share, and that the company is therefore in compliance with the nasdaq capital market's listing requirements. nasdaq also notified the company in the compliance notice that the hearing before the nasdaq hearings panel previously scheduled to take place on july 15, 2025, has been cancelled, and the company's securities will continue to be listed and traded on the nasdaq capital market.
DNA Ratings Summary
DNA Quant Ranking